NCT06359275View on ClinicalTrials.gov

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

PD-1

Toripalimab，240 mg/time，D1， Q3W

DRUG

Nab-paclitaxel

Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W

DRUG

Gemcitabine

Gemcitabine，1000mg/m2，IV，D1，8，Q3W

RADIATION

PULSAR

5-10 Gy per session, a total of 5 times.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanhai

All Listed Sponsors
lead

Fudan University

OTHER